


CORPORATE BROCHURE

ED. 2024/25



 **RECORDATI**

AT THE FOREFRONT OF LIFE-ENHANCING AND LIFE-CHANGING MEDICINES FOR ALMOST 100 YEARS

With our beginnings in a family-run pharmacy in Correggio, Italy in the 1920s, Recordati is now a global pharmaceutical group, listed on the Italian Stock Exchange since 1984, with around 4,580 employees.

Recordati is a group of passionate individuals who go to extraordinary lengths for partners, customers, investors, and the patients across the globe that it serves. We develop and commercialise medicines to serve people living with common diseases, as well as those living with some of the rarest.

At Recordati, we've always believed that health, and the opportunity to live life to the fullest, is a right, not a privilege. Whether that is for common diseases or the rarest, Recordati wants to give everyone the opportunity to be the best version of themselves. This drive will never stop.

Recordati has a long history of entrepreneurial passion, a strong reputation and a desire to continue growing, innovating and creating value in an ethical, enduring, and sustainable way, protecting people and the environment, and supplying safe, high-quality products.

Driven by its purpose, Recordati is focused on improving people's health and quality of life. We care for our people and strive to give them the opportunity and support to develop themselves. We pursue a long-term sustainable growth model, integrating social and environmental aspects into the corporate strategy, to make a positive contribution to sustainable development in the areas in which we operate. All this, while also always maintaining a commitment to generating value for stakeholders.

Recordati. Unlocking the full potential of life.



THE MILESTONES OF A LONG SUCCESS STORY



- 1926** Giovanni Recordati founds the Laboratorio Farmacologico Reggiano in Correggio (RE, Italy)
- 1927** Launch of Antispasmina Colica®, gastrointestinal tract antispasmodic
- 1953** Transfer of the headquarters to Milan
- 1961** Recordati - Syntex (now part of Roche) licence agreement. Located in Silicon Valley, Syntex was a pioneering company in the study and synthesis of steroid hormones
- 1963** Inauguration of the pharmaceutical chemical plant in Campoverde di Aprilia
- 1973** Launch of Urispas® (flavoxate), a urinary antispasmodic. Synthesized and developed by Recordati, it was the first Italian drug to receive FDA approval in the US



- 1995** Beginning of the process of internationalisation
- Establishment of a subsidiary in Spain
- 1997** Launch of Zandip® (lercanidipine), a new antihypertensive drug entirely discovered and developed by Recordati
- 1999** Acquisition of Doms Adrian (France)
- 2000** Acquisition of Bouchara (France)
- 2001** Establishment of Bouchara Recordati in France
- 2005** Acquisition of Merckle Recordati in Germany
- Establishment of Recordati in the United Kingdom
- Establishment of Recordati in Greece
- Establishment of the new pharmaceutical chemical plant in Cork, Ireland
- 2006** Acquisition of the Grupo Jaba companies in Portugal



- 2012** Entry into the US market - Rare Diseases sector
- Acquisition of a product portfolio for the treatment of a number of Rare Diseases in the US
- Acquisition of Farma-Projekt in Poland
- 2013** Acquisition of Opalia Pharma and its cGMP certified production facilities in Tunisia
- Acquisition of Laboratorios Casen Fleet and its cGMP certified production facilities in Spain
- 2014** US Food and Drug Administration (FDA) granted Orphan Drug Designation for the use of Carbaglu® in the treatment of organic acidemias
- 2015** Establishment of new subsidiaries in Brazil, Mexico and Colombia
- Carbaglu® authorized for sale in Canada for the treatment of NAGS deficiency



- 2019** Expansion of the Rare Diseases product portfolio: entry into the endocrinology sector
- Licence agreement in Japan for Juxtapid® (lomitapide), a treatment for the homozygous familial hypercholesterolemia (HoFH)
- Acquisition of worldwide rights to Signifor® (pasireotide) and Signifor® LAR® for the treatment of Cushing's disease and Acromegaly and to Isturisa® (osilodrostat) for the treatment of endogenous Cushing's syndrome in Europe
- Establishment of Recordati Bulgaria
- 2020** Marketing authorization of Cystadrops® 0.37% (cysteamine-based ophthalmic solution), for the treatment of Cystinosis patients in the USA
- Launch of Isturisa® in US, France and Germany, orphan pharmaceutical product approved by the European Commission and the Food and Drug Administration (FDA)
- Direct marketing of Signifor® and Signifor® LAR in the US
- Licence agreement with ARS Pharmaceuticals for ARS-1, epinephrine-based nasal spray

1926

Recordati was established

1984

Listing on the Italian Stock Exchange

1995

Beginning of the process of internationalisation

2007

Entry into the Rare Diseases sector

2012

Entry into the US market
Rare Diseases sector

2016

SPC and CHC portfolio strengthening

2019

Entry into the endocrinology sector
Rare Diseases

2021-24

Entry into niche oncology
Rare Diseases

- 1984** Listing on the Italian Stock Exchange
- 1986** Launch of Lomexin® (fenticonazole), a dermatological and gynecological anti-mycotic born in the Recordati research laboratories



- 2007** Entry into the Rare Diseases sector
- Acquisition of Orphan Europe, now Recordati Rare Diseases
- Launch of Zandipress® (lercanidipine + enalapril), antihypertensive developed by Recordati
- 2008** Acquisition of FIC and FIC Médical, dedicated to the registration and promotion of pharmaceutical products in Russia and other Commonwealth of Independent States (C.I.S.) countries
- Acquisition of Yeni İlaç in Türkiye
- 2009** Acquisition of Herbacos-Bofarma in the Czech Republic and Slovakia
- 2010** Launch of Urorec® (silodosin), an alpha blocker prescribed for the Benign Prostatic Hyperplasia (BPH) treatment
- Carbaglu® (carglumic acid) approved by the Food and Drug Administration (FDA) in the US for the treatment of NAGS deficiency
- Acquisition of ArtMed International in Romania, now Recordati Romania
- 2011** Extension of the indications for use of Carbaglu® in Europe
- Acquisition of Dr. F. Frik İlaç in Türkiye
- Launch of Livazo® - Alipza® (pitavastatin) for hypercholesterolemia in Europe
- Acquisition of Procto-Glyvenol®, a product prescribed for the treatment of haemorrhoids

LEGEND

Recordati

Specialty & Primary Care products (SPC)

Rare Diseases products

SPC acquisition, new companies and plants

Rare Diseases acquisition, new companies and plants

Licencing and commercial agreements



- 2016** SPC and CHC portfolio strengthening
- Acquisition of Italchimici in Italy
- Acquisition of Pro Farma AG, now Recordati AG, in Switzerland and Austria
- Agreement with Assistance Publique - Hôpitaux de Paris for the development of a product for the treatment of Maple Syrup Urine Disease (MSUD)
- Licence agreement with Gedeon Richter for the commercialisation of Reagila® (cariprazine) for the treatment of schizophrenia
- 2017** European marketing authorisation of Cystadrops® (cysteamine hydrochloride), eye drops for the local treatment of Cystinosis
- Acquisition of Seloken®/Seloken® ZOK (metoprolol succinate) and Logimax® (metoprolol succinate and felodipine) for a range of heart diseases
- Licence agreement with MimeTech for the development of a drug for the treatment of neurotrophic keratitis
- 2018** Acquisition of Cystagon® (cysteamine bitartrate) for the proven nephropathic Cystinosis
- Acquisition of Natural Point in Italy
- Exclusive licence agreement for the marketing of Ledaga® (chlormethine hydrochloride) for the topical treatment of mycosis fungoides
- Ledaga® is granted Orphan Drug Designation in Europe
- Acquisition of Tonipharma in France
- Launch of Reagila® (cariprazine) in Europe
- Establishment of new subsidiaries in Japan and Australia



- 2021-24** Expansion of the Rare Diseases product portfolio: entry into niche oncology
- Acquisition of EUSA Pharma (UK) Ltd, a global specialist pharmaceutical company focused on Rare Diseases and niche oncology
- Licence agreement and distribution of Eligard® (leuprorelin acetate), for the treatment of hormone-dependent prostate cancer in Europe, Türkiye, Russia and other countries
- Direct marketing of Eligard®
- New indication for Carbaglu® 200 mg tablets approved by the FDA in the US
- Acquisition of Flatoril® (clebopride plus simethicone) in Spain, for gastrointestinal disorders
- Launch of Isturisa® in Japan following approval by MHLW
- Establishment of a new subsidiary in China
- Agreement with GSK to commercialise Avodart® (dutasteride) and Combodart®/Duodart® (dutasteride/tamsulosin) for the treatment of Benign Prostatic Hyperplasia (BPH)
- Carbaglu® receives marketing authorisation in China
- Acquisition of global rights to Enjaymo® (sutimlimab)





TABLE OF CONTENTS

1. RECORDATI: TODAY AND THE FUTURE	7
• Our Journey into the Future	
• Our Company Culture	
2. RECORDATI'S KEY FIGURES	14
3. THE RECORDATI SHARE	17
4. RECORDATI IN THE WORLD	20
5. RECORDATI'S BUSINESSES AND PRODUCTS	23
• Specialty & Primary Care	
• Empowering Lives: SPC's 2024 Patient Support Initiatives	
• Rare Diseases	
• Focusing on the Few: RD's 2024 Patient Support Initiatives	
• Pharmaceutical Chemicals	
6. INDUSTRIAL OPERATIONS AT RECORDATI	39
• Production Facilities	
• Quality and Safety	
• Tech Transfer and Lifecycle Management	
7. RESEARCH & DEVELOPMENT AT RECORDATI	49
• Our Product Development Pipeline	
• Honouring excellence in Research: the Arrigo Recordati Prize	
8. PARTNERING WITH RECORDATI	53
• Our Business Development Strategy	
9. RECORDATI'S COMMITMENT TO SUSTAINABILITY	58
• Our Sustainability Plan	
• Support for Local Communities	

CONTINUING OUR GROWTH JOURNEY

SPECIALTY & PRIMARY CARE
2024 REVENUES

1,449.2

Million Euros
(64.4%)

RARE DISEASES
2024 REVENUES

833.8

Million Euros
(35.6%)

01. RECORDATI: TODAY AND THE FUTURE

**WE ARE CONTINUALLY GROWING,
WITH A FOCUS ON DEVELOPING
NEW SPECIALTIES, NEW
TREATMENTS AND INVESTING
IN MEDICAL INNOVATIONS THAT
BRING A BRIGHTER FUTURE TO
PATIENTS ACROSS THE WORLD.**

We are uniquely structured to bring treatment options across Specialty & Primary Care, Consumer Healthcare (CHC), and Rare Diseases.

- We have fully-integrated operations across Research & Development, chemical and finished product manufacturing through to commercialisation and licensing.
- We promote well-being.
- We have a diversified portfolio operating in around 150 countries worldwide.
- We are a partner of choice due to our unique structure.
- We maintain the highest quality and safety standards of our products throughout all their life cycle.
- We manufacture pharmaceutical ingredients to support our supply-chain, whilst also providing to customers worldwide.



We are based in Milan, Italy and have been listed on the Italian Stock Exchange since 1984.

We produce and promote a wide range of innovative products in around 150 countries.

We market a number of specialties generated by our original research.

Our portfolio includes both products for Specialty & Primary Care and treatments for Rare Diseases.



SPECIALTY & PRIMARY CARE



We have a strong and proven heritage of supporting people living with a wide range of common illnesses that affect large populations day-to-day.

We create value for patients, payers, and physicians across Specialty & Primary Care with both prescription and self-medication treatments, with a focus on cardiovascular, urological and uro-oncological, gastrointestinal areas.

We provide treatments globally, with direct presence in Europe, Türkiye and North Africa and have proven experience in supporting access to medicines throughout their lifecycle.

RARE DISEASES




Of the 7,000 known Rare Diseases, less than 10% have an available treatment option. Since 2007, through our dedicated business unit Recordati Rare Diseases, we've focused on helping the few who suffer from little known conditions.

Our mission is to reduce the impact of rare and devastating diseases by providing urgently needed medicines in key therapeutic areas including:

- Endocrinology.
- Hema-Oncology.
- Metabolic.

PHARMACEUTICAL CHEMICALS

We produce various active and intermediate ingredients which, in addition to meeting our own needs, we also sell to third-party pharmaceutical companies.



OUR JOURNEY INTO THE FUTURE

THE PROVEN ABILITY FOR CREATING PROFITABLE PARTNERSHIPS WITH IMPORTANT PLAYERS IN THE PHARMACEUTICAL SECTOR WILL CONTINUE TO SUPPORT US IN OUR QUEST TO IDENTIFY NEW OPPORTUNITIES AND FINALIZE NEW LICENCE AGREEMENTS FOR THE DEVELOPMENT OF HIGH-VALUE MEDICINAL PRODUCTS.

A WIDE AND DIFFUSED PRESENCE


With operations in all European countries, in Russia and in the C.I.S. countries, in Ukraine, Türkiye and North Africa, in the United States, Canada, Latin America, Japan, Australia, China and South Korea, we continue to strengthen our geographical presence.

We are also increasing our activities in Rare Diseases with the acquisition in November 2024 of the rights to Enjaymo®, a groundbreaking biologic and the only approved targeted treatment for Cold Agglutnin Disease (CAD), a rare and debilitating B-cells lymphoproliferative disorder. The transaction is an excellent fit with our existing businesses and reinforces our commitment to addressing the needs of patients with significant medical needs and limited treatment options.



M&A AND BUSINESS DEVELOPMENT

An integral part of the Recordati history



A STRONGER PRODUCT PORTFOLIO

The launch of innovative new products, the enhancement of our product portfolio with specialties from our own research and development or from targeted licence agreements or specific acquisitions, will boost our growth.

A CONSTANT INVESTMENT IN RESEARCH AND INNOVATION

We are committed to the innovation and marketing of high value-added products. We continuously develop new medicines and believe Research & Development is a fundamental basis for our growth. Dedication and scientific rigor are always behind our

specialties and Consumer Healthcare products, which are also produced with the highest levels of quality and safety.

A STRATEGIC PARTNER

We are an ideal partner for the development and marketing of new products in our markets thanks to:

- Our extensive geographical coverage.
- An efficient in-company network of medical representatives and orphan drug specialists.
- Our significant competence in handling regulatory processes.
- Our profound know-how in the handling of highly specialized products.



OUR COMPANY CULTURE

THE RECORDATI CULTURE IS BUILT ON THE PILLARS OF ENTREPRENEURSHIP, PURPOSE AND BELONGING. EXECUTION AND DISCIPLINE HAVE ALWAYS BEEN PART OF WHO RECORDATI IS AND WILL CONTINUE TO DRIVE THE COMPANY'S PERFORMANCE IN AN EVER-CHANGING, DYNAMIC ENVIRONMENT.

We strive to ensure everyone feels welcome, respected, supported in their professional and intellectual growth, and appreciated for their uniqueness and diverse talent. The energy, commitment and dedication of people are celebrated and rewarded, fairly and transparently. To support the people who work across Recordati, we continue to promote and showcase our culture, to allow people to be their full selves at work, feel safe to speak up and empowered to make decisions, experiment and innovate.


Recordati promotes initiatives to foster a more diverse and inclusive working environment for all, also with the aim of increasing the percentage of women in Top and Senior Manager positions. This year too, the Group ran a Culture Survey, targeting around 300 people Senior Leaders across the world to understand how the company culture has evolved. The results were very encouraging showing a continued positive trend in all dimensions year-on-year.



In 2024, Recordati launched its Employee Value Proposition (EVP) – or our promise to current and future employees of the value we offer in return for their skills, experience and commitment. Our EVP slogan reflects our purpose and is 'Ready to Unlock Your Full Potential?'

Recordati continues its dedication to fostering diversity and inclusion. In 2024, a Diversity & Inclusion network including around 60 champions across the world was set up to nurture this important culture pillar, with a first ambitious target to sign Diversity & Inclusion Charters in all European countries where we operate. The charters, as stated in the Code of Ethics, reinforce Recordati's commitment to fight all forms of discrimination in the workplace – gender, age, disability, ethnicity, religious beliefs, sexual orientation, and so on – and promote diversity and inclusion within the company.

As of December 31st 2024, Recordati has endorsed the European Diversity Charters in 13 European Union countries: Italy, Austria, France, Germany, Greece, Ireland, Poland, Portugal, the Czech Republic, Romania, Slovakia, Spain, and Sweden. In 2025, the Group will complete the signing of the European Diversity Charters in the remaining two countries: Belgium and the Netherlands, achieving this significant milestone.



2024, ANOTHER YEAR OF OUTSTANDING PERFORMANCE

 **REVENUE**
2,341.6
Million euros


 **EBITDA**
865.8
Million euros

 **ADJ. NET INCOME**
568.9
Million euros


02. RECORDATI'S KEY FIGURES

2024 was a year of outstanding performance. A number of new initiatives were pursued for the our future development.


REVENUE




EBITDA*




EBITDA* AS % OF REVENUE




RESEARCH & DEVELOPMENT




NET INCOME




ADJUSTED NET INCOME**




DIVIDEND PER SHARE



NET INCOME PER SHARE



ADJUSTED NET INCOME PER SHARE




PHARMACEUTICAL REVENUE BY THERAPEUTIC AREA

SPECIALTY & PRIMARY CARE 64.4%

RARE DISEASES 35.6%




PHARMACEUTICAL REVENUE BY GEOGRAPHY



BALANCE SHEET

as of 31 December 2024



* Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory according to IFRS 3.

** Net income excluding the amortization and write-down of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory pursuant to IFRS 3, and monetary net gains/losses from hyperinflation (IAS 29), net of tax effects.




LISTED ON THE ITALIAN STOCK EXCHANGE SINCE 1984

03. THE RECORDATI SHARE




DIVIDEND

(Euro per Share)



PRINCIPAL SHAREHOLDERS

as of 31 December 2024



THE RECORDATI SHARE as of 31 December 2024

Listing	Borsa Italiana, Blue Chip segment, healthcare
ISIN Code	It 0003828271
Ticker	Bloomberg REC IM, Reuters RECI.MI
Index	FTSE MIB, FTSE Italia All-Share Health Care Index, FTSE Italia All-Share Pharmaceuticals & Biotechnology Index, FTSE4Good Index Series, STOXX Europe 600, Euro STOXX Health Care, MSCI Indexes
Share Capital	n. 209,125,156 common shares
Nominal value	€ 0.125 per share
EPS (diluted)	€ 1.992
Dividend per share	€ 1.27



HEADQUARTERS IN MILAN, ACTIVITIES WORLDWIDE



EMPLOYEES

> **4,580**




MARKETS

~**150**

04. RECORDATI IN THE WORLD


We are present* in around 150 countries with our Specialty & Primary Care products and our treatments for Rare Diseases.

SPECIALTY & PRIMARY CARE



- Subsidiaries, branches, permanent establishment and direct promotion**
Armenia, Austria, Belarus, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Iceland, Ireland, Italy, Kazakhstan, Latvia, Lithuania, Luxembourg, Mongolia, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, San Marino, Slovakia, Spain, Sweden, Switzerland, Tunisia, Türkiye, Turkmenistan, Ukraine, United Kingdom, Uzbekistan.
- Licensees, distributors, commercial agreements**
Albania, Algeria, Angola, Argentina, Australia, Azerbaijan, Benin, Bosnia and Herzegovina, Brazil, Burkina Faso, Cambodia, Cameroon, Cape Verde, Central African Republic, Chad, Chile, China, Colombia, Congo (Rep.), Croatia, Cyprus, Djibouti, Dominican Republic, Ecuador, French Guiana, French Polynesia, Gabon, Guadeloupe, Guatemala, Guinea, Hong Kong, Hungary, Indonesia, Iraq, Israel, Ivory Coast, Japan, Jordan, Kenya, Kosovo, Kyrgyzstan, Lebanon, Libya, Macedonia, Madagascar, Malaysia, Mali, Martinique, Mauritania, Mauritius, Mayotte, Mexico, Moldova, Morocco, New Caledonia, New Zealand, Niger, Paraguay, Philippines, Réunion, Saudi Arabia, Senegal, Serbia, Singapore, Slovenia, South Africa, South Korea, Sri Lanka, Taiwan, Tajikistan, Tanzania, Thailand, Togo, United Arab Emirates, Uruguay, Vatican City State, Venezuela, Vietnam, Wallis and Futuna.


GEOGRAPHICAL COMPOSITION OF PHARMACEUTICAL SALES IN 2024



* Years 2023-2024.




RARE DISEASES



- Subsidiaries, branches, permanent establishment and direct promotion**
Algeria, Andorra, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Canada, China, Colombia, Cyprus, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Iran, Iraq, Ireland, Italy, Japan, Jordan, Kuwait, Latvia, Lebanon, Libya, Lithuania, Luxembourg, Malta, Mexico, Morocco, Netherlands, New Zealand, Norway, Oman, Poland, Portugal, Qatar, Russian Federation, Saudi Arabia, Slovakia, Slovenia, South Korea, Spain, Sweden, Switzerland, Tunisia, Türkiye, United Arab Emirates, United Kingdom, United States of America.
- Licensees, distributors, commercial agreements**
Azerbaijan, Belarus, Brunei Darussalam, Bulgaria, Chile, Costa Rica, Croatia, Dominican Republic, Georgia, Guatemala, Haiti, Honduras, Hong Kong, India, Indonesia, Israel, Jamaica, Kazakhstan, Macao, Macedonia, Malaysia, Mauritania, Mongolia, Montenegro, Pakistan, Paraguay, Peru, Philippines, Romania, Rwanda, Serbia, Singapore, South Africa, Sri Lanka, Taiwan, Thailand, Ukraine, Uruguay, Venezuela, Vietnam, Zambia.

GEOGRAPHICAL COMPOSITION OF PHARMACEUTICAL SALES IN 2024



05. RECORDATI'S BUSINESSES AND PRODUCTS

Always committed to giving people the opportunity to unlock the full potential of life, we offer a number of innovative and high value-adding pharmaceutical products that constitute a large and qualified product portfolio.

BREAKDOWN OF REVENUE 2024

SPECIALTY & PRIMARY CARE 64.4%

17.1%
Urology

16.4%
Cardiovascular

13.2%
Other areas

9.3%
Gastro & intestinal



RARE DISEASES 35.6%

SPECIALTY & PRIMARY CARE



**WE MAKE MANY MEDICINES,
AVAILABLE IN VARIOUS
THERAPEUTIC AREAS
ACROSS EUROPE, TÜRKIYE,
RUSSIA AND NORTH AFRICA.**

Around
400 BRANDS

PRESCRIPTION MEDICINES

We have a significant presence in this field and offer established treatments in the areas of cardiovascular, urological and uro-oncological, gastrointestinal diseases. We market products developed from our own research and by specific licence agreements.

CONSUMER HEALTHCARE

We offer several well-established brands, across a large range of therapeutic areas, such as digestive health, women's health & intimate care, and vitamins & minerals, as well as food supplements.

AT THE HEART OF WE DO

MAIN PRESCRIPTION MEDICINES	
CARDIOVASCULAR	
ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine) Antihypertensive	COMBODART®/DUODART® (dutasteride/tamsulosin)* Benign Prostatic Hyperplasia (BPH)
ZANIPRESS®/ZANEXTRA®/LERCAPREL®/ LERCARIL® (lercanidipine + enalapril) Antihypertensive	UROREC®/SILODYX® (silodosin) Benign Prostatic Hyperplasia (BPH)
SELOKEN®/SELOKEN®ZOK/BETALOK®ZOK (metoprolol succinate) Angina pectoris, disturbances of cardiac rhythm, hypertension	GASTROENTEROLOGY
LOGIMAX® (metoprolol succinate + felodipine) Antihypertensive	CITRAFLEET® (citric acid) and PHOSPHOSODA® (sodium dihydrogen phosphate dihydrate) Bowel evacuants
LOPRESOR® (metoprolol) Antihypertensive	CASENLAX® (macrogol) and FLEET ENEMA® (monobasic sodium phosphate) Constipation and bowel cleansing
LIVAZO®/ALIPZA® (pitavastatin) Hypercholesterolaemia	COUGH & COLD
UROLOGY AND URO-ONCOLOGY	POLYDEXA® (neomycin sulfate) Treatment of ear infections
ELIGARD® (leuporelin acetate) Hormone dependent advanced prostate cancer	ISOFRA® (framycetin sulfate) Treatment of nose and throat infections
AVODART® (dutasteride)* Benign Prostatic Hyperplasia (BPH)	OTHER
	REAGILA® (cariprazine) Antipsychotic
	TERGYNAN® (metronidazole) Gynecological infections

* Trademarks are owned by or licensed to the GSK group of companies. Transition to Recordati of commercialization of Avodart® and Combodart®/Duodart® has been enacted in the following markets: Austria, Belgium, Czech Republic, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Poland, Portugal, Spain, Sweden, Switzerland, UK.

MAIN CONSUMER HEALTHCARE BRANDS	
PROCTO-GLYVENOL® (tribenoside + lidocaine), PROCTOLYN® (fluocinolone acetonide + chetocaine hydrochloride) Treatment of haemorrhoids	GINKOR® (ginkgo biloba) Venotonics
MAGNESIO SUPREMO® (magnesium carbonate) Food supplement	HEXASPRAY® (biclotymol) Antibacterial for sore throat
LOMEXIN®/FALVIN®/GYNOXIN® (fenticonazole) Antifungal	ALOVEX®/ALOCLAIR® (hyaluronic acid) Oral care - mouth sores
REUFLO®R, REUTERI®, CASENBIOTIC®, BIORALSUERO® (lactobacillus reuteri protectis) Probiotics	EUMILL® (natural moisturizers/hyaluronic acid) Eye care

LOCAL BRANDS

Our portfolio also consists of a number of local brands, promoted by our subsidiaries who have established a strong presence in their respective markets.

ITALY

In Italy, we are committed to the development and commercialisation of medicines as well as CHC brands.

Regarding prescription medicines, in addition to our consolidated presence in the cardiometabolic area, we offer a unique and complete portfolio for the treatment of urological diseases (BPH, prostate cancer, sexual dysfunction), treatments for respiratory and allergic diseases with a specific focus on paediatric patients, as well as treatments in the gastrointestinal and analgesia areas. We also have a broad offering of self-medications with a focus on food supplements, oral hygiene, eye care, and gastrointestinal remedies.

Historic brands include Proctolyn®, Alovex®, Eumill®, Dentosan®, Imidazyl®.

Among food supplements, Magnesio Supremo® represents a successful example of our company’s commitment to innovation and offering a wide range of new products to meet consumers’ needs. Recently, the line was further expanded with the launch of Magnesio Supremo® Potassio+, enhancing our range of products designed to support well-being during the summer months. In addition, Reuflor®, a leading probiotic in the paediatric area, is leveraging its expertise to expand into the adult population through new line extensions, aiming to become the microbiota reference across all age groups.

FRANCE

Recordati is a prominent name in the French market, known for its diverse range of prescription medicines targeting key therapeutic areas such as cardiology, urology, and addiction. Additionally, our CHC line includes well-established brands with a long-standing and solid performance in markets



such as cough & cold, with Hexaspray® for sore throat and Exomuc® for cough; venotonics, with Ginkor® for heavy legs and hemorrhoids; and oral care, with Alodont®, all supported by ongoing efforts to foster innovation and better meet patients’ needs.

SPAIN

Recordati in Spain has an extensive and substantial portfolio of medicines. In the area of urology and uro-oncology, our broad portfolio includes Eligard® for men with advanced prostate cancer while in BPH we market well-established brands as Avodart® (named Avidart® in Spain), Duodart® and Urorec®. In gastroenterology, our brands for bowel cleansing and oral rehydration are undisputed market leaders and in addition, we have products in paediatrics, gynecology and psychiatry.





GERMANY

Recordati is well-established in Germany with a strong and growing presence in key therapeutic areas such as urology, orthopedics, and CNS. We offer a wide range of therapeutic solutions to healthcare professionals and their patients, and we are one of the most well-known German pharmaceutical companies in the field of orthopedics. In addition to our prescription brands, our portfolio includes well-known CHC products offering solutions in gastroenterology (Laxbene®), cough & cold (Rhinoprant®, JHP® Rödler), wound and skin care (Mirfulan®), and sleep disorders (Betadorm®).

To unlock the full potential of our self-medication business, a dedicated unit was launched in 2024.

RUSSIA, UKRAINE, OTHER C.I.S. COUNTRIES, AND CENTRAL ASIA

Our operations in Russia, Ukraine, the other C.I.S. markets and Central Asia successfully market medicines for otorhinolaryngological and vaginal infections, holding a leading position in their markets. The portfolio also includes popular CHC brands, such as the well-

known supplements Alfavit® and Qudesan®, OTC drugs like the oral antibacterials Hexaspray® and Hexalyse®, and the intestinal absorbent White Carbo®.

TÜRKIYE

Recordati markets a diversified portfolio, well appreciated by practitioners, in the fields of urology, uro-oncology, cardiology, surgery, gynecology and physical medicine and rehabilitation.

NORTH AFRICA

In North Africa and in Tunisia, we are one of the largest local pharmaceutical companies marketing branded generics, with leading products in cardiology, dermatology, gastrointestinal and respiratory therapeutic areas.

OTHER COUNTRIES

We have strengthened our presence in Switzerland with headquarters in Zug, and operations in Austria, Portugal, UK, Ireland, Greece, Sweden, Denmark, Norway, Finland, Iceland, Benelux, Czech Republic and Slovakia, Romania, Bulgaria, Poland and in the Baltic States.


EMPOWERING LIVES: SPC'S 2024 PATIENT SUPPORT INITIATIVES

AT SPC, WE ARE COMMITTED TO EMPOWERING PATIENTS WITH THE KNOWLEDGE AND SUPPORT THEY NEED TO NAVIGATE THEIR DIAGNOSIS AND MAXIMISE THE BENEFITS OF THEIR TREATMENTS, ALL WHILE PROMOTING OVERALL WELLBEING.

In 2024, we launched several initiatives to enhance patient care and education. Among these were:

GO BEYOND (FOR MEN WITH PROSTATE CANCER)

A prostate cancer diagnosis can leave many men feeling uncertain, lost, and even disconnected from their sense of self. The journey beyond diagnosis is often filled with questions – what comes next, and how can life be truly lived beyond the disease? GO BEYOND is the heart of SPC's Patient Support Initiatives – a commitment from Recordati to stand by men as they navigate this new chapter, providing robust resources containing the knowledge, tools, and guidance needed to help men regain confidence, purpose, and a renewed



sense of identity. With practical strategies, SPC strives to offer comprehensive physical and psychological support—equipping men with the skills to take control, rebuild their strength, and embrace life beyond cancer.

THE CANDID BOOK (FOR FAMILIES OF PEOPLE LIVING WITH SCHIZOPHRENIA)

The Candid Book helps families of people living with schizophrenia to shape their role as a caregiver, solving dilemmas and answering questions. Written by experts in the field, the authors speak directly to everyone affected by schizophrenia, regardless of the role they play.


ANTI-CYBERBULLYING CAMPAIGN

In an era where digital presence is an integral part of young people's daily lives, cyberbullying is not just a social issue but a real threat to mental health and wellbeing, affecting up to 30% of students in Italy, with hundreds of cases reported to the police each year.

With its core message "Feel the Care", Alovex®—Recordati's leading brand for mouth ulcer treatment—extended its commitment to protection and wellbeing beyond physical discomfort. Recognizing that cyberbullying, much like mouth ulcers, causes pain and distress that often goes unnoticed, the brand took action to support teenagers facing this issue.

In partnership with Bulli Stop, a specialized association, the campaign launched in December 2023 in Rome with an event at a high school. The initiative shed light on the severe consequences of cyberbullying through first-hand victim testimonies, followed by a series of interconnected activities aimed at raising awareness and encouraging affected students to seek help.

The initiative led to a 70% increase in requests for help to the Bulli Stop Association, with a growing number of schools eager to promote awareness, plus remarkable digital engagement metrics.



RARE DISEASES

WE OPERATE IN THE RARE DISEASES SEGMENT WORLDWIDE THROUGH RECORDATI RARE DISEASES.



We research, develop, produce and market drugs for the treatment of a number of rare diseases. These are marketed directly in Europe, the Middle East, US, Canada, Russia, Türkiye and North Africa, Japan, Australia, new Zeland, China, South Korea and in some Latin American countries, and through selected partners in a number of other countries, covering 98 countries worldwide.

Highly-trained specialists and scientific support teams collaborate constantly with researchers, medical practitioners and health care professionals, with patient groups and families and with regulators to treat and improve the quality of life of people suffering from these diseases worldwide.

Thanks to a unique distribution system and to specialists dedicated to the promotion and distribution of these products, we are able to reach patients in their home countries.

ENDOCRINOLOGY

Your endocrine system is comprised of a network of glands in your body that produces and secretes hormones.

Hormones are chemical messengers that carry information and instructions from one part of the body to another, that control or regulate many bodily functions, including

growth and development, metabolism, reproduction, and mood, among others. Many diseases may impact how the varied endocrine glands work in the body, resulting in disordered hormone production and secretion, which may underlie burdensome and, in some cases, life-threatening syndromes and conditions if left untreated. Some of these diseases are rare and only affect a few people globally.

These conditions are often difficult to diagnose due to lack of awareness of varied signs and symptoms, which can result in delayed diagnosis and/or undertreatment.

Recordati Rare Diseases is focused on targeting endocrine conditions associated with high unmet need and burden, and is committed to providing better treatment options and solutions for patients, with a particular focus on improving the lives of those suffering from pituitary and adrenal gland dysfunctions or related conditions, which can impact growth and metabolism imbalances.

Around
100 COUNTRIES
worldwide (direct and indirect sales)



HEMA-ONCOLOGY

The human body is made up of trillions of cells. When these cells become old or damaged, they die, and need to be replaced with new ones. Normally, human cells grow and multiply through cell division to create these new cells as they are needed. This cell division and cell growth is self-regulated and self-limited in normal conditions. Sometimes, however, this process doesn't happen as it should – and abnormal or damaged cells (so-called mutated cancer cells) can grow where they shouldn't, sometimes forming harmful cancerous tumours. Cancerous tumours can start anywhere and spread to other parts of the body; these are called malignant tumours. Tumours can also be

benign, meaning they grow but they don't spread through the body and tend not to create problems. Recordati Rare Diseases focuses on some of the rarest cancers, in both adult and paediatric indications, where very few treatment options exist.

METABOLIC

Metabolic diseases can be caused by several genetic defects, causing abnormal accumulation of metabolites and/or defects in others. These inborn errors of metabolism affect neonates, children and adults. Since it was founded, Recordati Rare Diseases has been focussing on rare metabolic conditions, many of which can be difficult to diagnose and can be life-threatening.



#ThisCushing is a global initiative developed by Recordati Rare Diseases in collaboration with an award-winning photographer and internationally-recognised experts in the field of pituitary endocrinological diseases.
thisiscushing.com

MAIN DRUGS FOR THE TREATMENT OF RARE DISEASES

ENDOCRINOLOGY

SIGNIFOR® and SIGNIFOR® LAR (pasireotide)
Treatment of Cushing's Disease and Acromegaly

ISTURISA® (osilodrostat)
Treatment of Cushing's Disease (United States) and Cushing's Syndrome (European Union, Japan, Switzerland)

HEMA-ONCOLOGY

QARZIBA® (dinutuximab beta, anti-GD2 monoclonal antibody)
Treatment of high-risk neuroblastoma patients aged 12 months and above, who achieved at least a partial response at the chemotherapeutical induction, followed by myeloablative therapy and stem cell transplantation

SYLVANT® (siltuximab, anti-IL-6 monoclonal antibody)
Treatment of idiopathic Multicentric Castleman's Disease (iMCD) in the adult population

FOTIVDA® (tivozanib, highly selective oral Tyrosine Kinase Inhibitor (TKI) for Vascular Endothelial Growth Factor (VEGF) receptors 1, 2 and 3)
First-line treatment for advanced Renal Cell Carcinoma (RCC)

CAPHOSOL® (mouthwash with supersaturated electrolytic solution of phosphate and calcium ions)
Prescription medical device for treatment of oral mucositis due to chemo and radiation therapy

ENJAYMO® (sutimlimab, c1s complement inhibitor monoclonal antibody)
Treatment of hemolysis in adults with Cold Agglutinin Disease (CAD)

METABOLIC AND OTHER DISEASE TREATMENT AREAS

CARBAGLU® (carglumic acid)
Treatment of hyperammonemia due to N-AcetylGlutamate Synthase deficiency (NAGS deficiency) and some organic acidemia (isovaleric acidemia, methylmalonic acidemia and propionic acidemia)

NORMOSANG®/PANHEMATIN® (human hemin)
Treatment of acute attacks of hepatic porphyria

CYSTADANE® (betaine anhydrous)
Treatment of homocystinuria

CYSTADROPS® (cysteamine hydrochloride)
Treatment of the ocular manifestations of Cystinosis

JUXTAPID® (lomitapide)
Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

CYSTAGON® (cysteamine bitartrate)
Treatment of nephropathic Cystinosis

LEDAGA® (chlormethine hydrochloride)
Treatment of Mycosis Fungoides (MF), T-Cell Cutaneous Lymphoma (CTCL)

PEDEA®/NEOPROFEN® (IV ibuprofene)
Treatment of Patent Ductus Arteriosus (PDA)



INTERNATIONAL AWARDS

We have an established track record in the field of orphan drug development. The establishment of scientific networks and engaging with patient organisations together with our efforts to reduce the impact of disease on the lives of patients are the reasons that have contributed to winning prestigious international awards and that push us to continue in this direction every day.

Our Rare Diseases teams have received recognition for their work to raise awareness of Cushing's syndrome, with the #THISCUSHING campaign winning accolades at the International Content Marketing Awards.



These awards demonstrate the continued success of the campaign, which previously won the award for 'Patient-Centricity' at the Pharmaceutical Market Excellence Awards (PMEA) 2023, with the PharmaTimes naming Stefano de Socio from the campaign team as 2023 "Marketer of the Year".



The campaign was presented with the Silver Award for Best Specialist Campaign, and the Bronze Award for the Best Use of Imagery.



The results obtained in improving the diagnosis and management of Rare Diseases were recognised by EURORDIS (European Organization for Rare Diseases) with an award that was presented to us during the celebration of the 2014 Rare Disease Day.



Our commitment to making our products available to patients suffering from Rare Diseases was recognised by the National Organization for Rare Disorders (NORD) in the United States with its "Corporate Award".

This important award was granted in 2011 in recognition of the introduction into the United States of Carbaglu®, the first specific treatment approved by the FDA (Food and Drug Administration) for NAGS deficiency, a very rare inherited metabolic disease.

FOCUSING ON THE FEW: RD'S 2024 PATIENT SUPPORT INITIATIVES

RARE DISEASES IS INVOLVED IN SEVERAL INITIATIVES AIMED AT SUPPORTING PATIENTS AND PATIENT ASSOCIATIONS FOR PEOPLE AFFECTED BY RARE DISEASES, WHICH HELP TO FACILITATE ACCESS TO ORPHAN DRUGS AND TREATMENT CENTRES.

Recordati's orphan drug specialists actively collaborate with the medical community to facilitate dialogue between hospitals with limited expertise in rare diseases and specialist medical centres able to diagnose and treat rare conditions in an appropriate manner.

Also, in the context of facilitating access to treatments, in 2024 Rare Diseases continued to support two programmes to provide assistance to patients eligible to receive support for the costs related to its products: the Patient Assistance Program and the Co-Pay Assistance Program.

In 2024, Rare Diseases continued to work closely with rare disease communities to increase awareness of rare diseases, leading to improved diagnosis, and expanding availability of treatments for those affected. It pursued this goal, for example, through meetings with

healthcare professionals, providing disease education to raise awareness (e.g. printed and digital brochures, websites and videos, but also through the Patient Advocacy Liaison programme for patients who are taking our products) and actively participating in scientific conferences.

The business was also involved in various collaborations with groups and associations (such as the American Porphyria Foundation, HCU Network America and Castleman Disease Collaborative Network) to provide disease education to patients and sponsor awareness-raising days.

In countries with a lack of infrastructure and with a considerable level of poverty, Rare Diseases covered for the diagnostic exams required to identify some of the conditions affecting our patients, thus implementing a key initiative to accelerate diagnose of rare and complex diseases.



RECORDATI RARE DISEASES FONDATION D'ENTREPRISE



The Recordati Rare Diseases Foundation was established to provide independent and unconditional support for training programmes aimed at the scientific community in the field of rare diseases. The overall objective is to share experience in the diagnosis, management and outcome of rare disorders, giving specialists the opportunity to broaden their expertise, develop new ideas and establish scientific relationships. A number of live events are held each year bringing together patients and patient association testimonials, clinicians and scientists from all over the world to discuss innovations, new diagnostic and management strategies. In 2024, three live medical education courses were organised in Endocrinology and Inborn Errors of Metabolism, confirming the role of the Foundation as a key player in medical education in these fields.

In 2025, the Foundation celebrated its first 25 years of activity and has delivered over 70 courses to over 3,000 health care professionals since its creation.

OUR COMMITMENT TO THE PATIENT COMMUNITY

At Recordati we focus on the few, those affected by rare diseases, and we believe that every single patient has the right to the best possible treatment. Patients with rare diseases

are our top priority. They are at the core of our planning, our thinking and our actions.

For us, patient centricity represents a partnership with the patient community, ensuring that their voices are integral to creating effective, patient-aligned healthcare solutions. This enables RD to prioritise, understand and address the patient community needs, preferences, and experiences. This approach ultimately aims to improve overall health outcomes by aligning medicines with what patients truly need. Being patient-centric at Recordati means actively listening to patients, understanding their journey and their struggles, trying to put ourselves in their shoes and shape our plans in a way that we can properly respond to their needs. We actively support and engage with patient organisations globally, in line with policies.

RD has a strong commitment to the early-stage design of clinical trials and research and development where there is a focus on involving patient associations and patient feedback, important for protocol development, as well as exploring life-cycle opportunities to deliver medicines that truly meet the needs of the patients

"The Patient Community" is a group of individuals who share similar health experiences or conditions and come together to provide mutual support, share knowledge, and advocate for better care. These communities consist of people living with rare diseases, their families and caregivers as well as patient advocates, all with the common goal of improving health outcomes and quality of life for those affected by rare diseases.



PATIENT COMMUNITY CHARTER

OUR PROMISE TO KEEP THE PATIENT COMMUNITY AT THE HEART OF ALL WE DO.

At Recordati Rare Diseases, patients with rare diseases are our top priority. They are at the core of our planning, our thinking and our actions.

This Charter embodies our commitment to the patient community; it guides how we act and understand and respond to their needs. It helps us to uphold our promise to always behave ethically and act responsibly.

Scott Pescatore
Executive Vice President Rare Diseases

Our approach towards patients is evident in the projects we initiated during 2024: the Patient Ambassador Group and the development of the Patient Community Charter together with our patient community. As Patient Ambassadors, we focus on working together with the patient community adding value by listening to their needs and co-creating solutions. In 2024, we made some important steps to formalise this through our Patient Community Charter and actions including our membership of PFMD, staff training to engage and collaborate in an ethically compliant manner, and the development of a fair market value calculator for the patient community that will ensure we commit to remuneration corrected for any services and time that they provide.

OUR PATIENT COMMUNITY CHARTER

Our Patient Community Charter underscores our unwavering commitment to embedding the voices and needs of patients with rare diseases

into every aspect of our work. This Charter aspires to position Rare Diseases as a trusted partner within the rare disease community, ensuring that patient input meaningfully shapes our actions, decisions, and outcomes. The Charter was developed in the EMEA region, and we plan to extend it globally.

Q BAG FOR CHILDREN UNDERGOING HIGH RISK NEUROBLASTOMA TREATMENT (GOLD PATIENT PARTNERSHIP INDEX (PPI) AWARD)

Rare Diseases' partnership with the Dutch Childhood Cancer Association (VKKN), as well as the patient community at Princess Maxima Paediatric Oncology Center, The Netherlands, achieved some outstanding real-world results. This partnership began informally as a result of children and their families reporting their experiences undergoing continuous IV immunotherapy for high-risk

neuroblastoma (HRNB). Infusion pumps are normally attached to an IV-polls or carried in a shoulder bag. However, both of these options can be restrictive for children. Inspired by one parent of a child undergoing continuous IV immunotherapy, Rare Diseases worked with Princess Maxima Hospital and a specialist design agency to develop a safe and robust backpack for IV pumps, the Q-bag.

Throughout development, children and families were continuously consulted, to ensure the bags were both user-friendly and appealing to the children for whom they were designed, with user feedback prompting multiple revisions. All children with HNRB in the Netherlands now receive a Q-bag for immunotherapy, which has numerous bespoke safety features and personalised design options. We are currently focussed on the roll out of the Q-bag across other territories. We are proud and privileged to be part of the Q-Bag Project. It was truly a collaborative effort from start to finish from a diverse range of stakeholders, all of which had a simple focus in mind: improving the quality of care for young people undergoing treatment for neuroblastoma.



Entering the PPI was an opportunity for us to inform, refine and benchmark our various patient community partnerships against best practice. Thus, further enabling us to commit to strong collaborative relationships with the rare disease patient community and continue our efforts to co-create sustainable solutions that have a meaningful impact on people living with rare conditions.

In Colombia, our efforts to reach patients have been made since the beginning of our business. We have evolved to provide two significant programmes to serve our community:

1. DIAGNOSTIC SUPPORT PROGRAM (DSP) for physicians to reach us when they suspect a patient may have one of our orphan diseases and need diagnostic confirmation.

2. PATIENT SUPPORT PROGRAM (PSP) where we commit to following up with our patients and educate them and their caregivers in disease, treatment, importance of adherence. We also design annual activities such as workshops and meetings where patients connect with each other to make a stronger network.


PHARMACEUTICAL CHEMICALS

WE USE A BROAD RANGE OF TECHNOLOGIES TO PRODUCE COMPETITIVELY, MAINTAINING THE HIGHEST QUALITY STANDARDS.

Our pharmaceutical chemicals business focuses on:

- Satisfying the requirements of the pharmaceuticals business.
- Striving for maximum product quality.
- Strengthening our presence in highly regulated markets (the United States, Europe and Japan).
- Safety of production processes.
- Protection of the environment.
- Health and safety in the workplace.

GEOGRAPHICAL COMPOSITION OF PHARMACEUTICAL CHEMICALS SALES IN 2024



2 DEDICATED SITES

Campoverde di Aprilia (Italy) and Cork (Ireland)



**A VAST
RANGE OF
COMPETENCIES**

06. INDUSTRIAL OPERATIONS AT RECORDATI

THE COMPANY OPERATES SEVERAL STATE-OF-THE-ART PRODUCTION SITES WHERE THE MANUFACTURING OF FINISHED PRODUCTS AND ACTIVE INGREDIENTS HAS BEEN CLOSELY LINKED WITH PHARMACEUTICAL ACTIVITIES SINCE THE BEGINNING OF THE COMPANY'S HISTORY.

Recordati currently has 10 manufacturing sites across the world, producing various pharmaceutical forms.

The company also operates a global network that includes over 150 contract manufacturing organisations (CMOs) and 50 warehouses, delivering more than 340 million units of medicines and therapies worldwide.

RECORDATI INDUSTRIAL OPERATIONS GLOBAL INFRASTRUCTURE



7 PHARMA
MANUFACTURING SITES



1 PACKAGING AND
DISTRIBUTION
CENTRE FOR RRD



2 ACTIVE PHARMACEUTICAL
INGREDIENTS (API) SITES



150+
CONTRACT
MANUFACTURING
ORGANISATIONS (CMO)

50+ 
WAREHOUSES

150+ 
COUNTRIES REACHED

ABOUT
340 MILLION
UNITS
DELIVERED ACROSS
THE GLOBE 



PRODUCTION FACILITIES

OUR PRODUCTION SITES ARE EQUIPPED WITH STATE-OF-THE-ART INSTALLATIONS AND OUR RESEARCH LABORATORIES ARE FITTED WITH THE LATEST EQUIPMENT.

All plants operate in full compliance with environmental protection regulations and in compliance with the cGMP (current Good Manufacturing Practices).



PHARMACEUTICAL MANUFACTURING PLANTS

ITALY

The Milan site occupies a surface area of around 5,000 sq.m., built vertically over a number of floors for a total of 21,000 sq.m. and produces around 70 million units per year. It is specialized in the manufacture and packaging of solid oral forms, liquids, and semi-solids for topical use. Recordati has undertaken a restructuring project in certain production areas, including the installation of a new blister packaging line, which has been added to the five already in place with potential additional free capacity.

FRANCE

The plant at Saint Victor covers a surface of 6,750 sq.m. and produces 30 million units per year. It is specialized in the production and packaging of liquid, solid oral and spray formulations.

SPAIN

The Spanish plant is situated near Zaragoza, covering a surface area of 7,100 sq.m. and producing around 24 million units a year.


It is specialised in the production and packaging of solid and liquid oral and topical formulations. In particular, the plant manufactures a line of gastroenterological products; furthermore a packaging-line was installed and approved few years ago for the packaging of tablets in bottles.

In 2024, the full insourcing of packaging step of metoprolol tablets in bottle was finalised. In relation to Recordati's environmental commitment, the project to install a photovoltaic solar panel system with the capacity to generate up to 185 kWp of electricity for self-consumption has been successfully completed; in 2023, a new project for increasing the capacity up to around 480 kWp started with the aim to complete it during 2025.

TÜRKİYE

The Turkish site is in Çerkezköy, Türkiye, built on 45,000 sq.m. of land, and covering approximately 11,300 sq.m.. It currently produces around 70 million units per year of





solid oral and liquid formulations and products for topical use, of which 25% are for other pharmaceutical companies. The project for the installation of a new liquid line started in 2023 and will be completed in 2025 allowing a significant increase of the production capacity and increasing internalisation of some liquid forms.

Additionally, an investment of a new blister line was approved to insource other two products and support the organic growth.

The Çerkezköy plant, in addition to the Turkish market, is authorized to produce medicines for the European Union, Azerbaijan, Libya, Kenya, the Russian Federation, Kyrgyzstan and Kazakhstan. In relation to our environmental commitment, the project to install a photovoltaic solar panel system with the capacity to generate up to around 480 kWp of electricity for self-consumption was completed in 2024.

TUNISIA

The site is situated in Ariana, near Tunis. It covers an area of around 9,100 sq.m. and produces around 19 million units a year of liquid, semi-solid and oral solid forms for the local market and for some of the countries in the Arabian Peninsula. Certified GMP compliant, the manufacturing site was approved by the Gulf Health Council and the Saudi Food and Drug Authority.

In 2023, a project to expand the existing warehouse was approved; in 2024 all the detailed engineering was developed and the permit for construction was obtained. It should be completed by the end of 2026. Additionally, the investment for a new automatic blister and cartoner machine was approved and the line will be fully operational in 2025. In relation to Recordati's environmental commitment, the project to install a photovoltaic solar panel system with the capacity to generate up to around 740 kWp of electricity for self-consumption already started in 2023 and will be completed in 2025.

SWITZERLAND

The facility, acquired in 2022 through agreements with Novartis for the acquisition of the rights to Signifor®, are located in the north-western part of Switzerland, Basel (within the Novartis Campus). The plant covers an area of approx. 1,500 sq.m. Since the successful qualification in 2012 and GMP certification by Swissmedic, it is used for commercial production of Signifor® LAR Bulk – a specialised drug product used for the treatment of Acromegaly and Cushing's Disease.

CZECH REPUBLIC

The plant, situated in Pardubice, produces creams, gels and ointments for a total of two million units per year.



PACKAGING AND DISTRIBUTION CENTER DEDICATED TO PRODUCTS FOR RARE DISEASES

A packaging and distribution site in Nanterre, near Paris, exclusively for products for the treatment of rare diseases is in operation. It occupies a surface area of 1,600 sq.m. and is entirely dedicated to the secondary packaging, storage and shipping of Rare Diseases products.

The site delivers, upon short notice, more than 27,000 orders annually to more than 60 countries worldwide thanks to its highly qualified staff and a modern GDP (Good Distribution Practices) certified logistics platform.

In 2025, the plant will begin insourcing of secondary packaging activities of Enjaymo® for the European market.

PHARMACEUTICAL CHEMICAL PLANTS

CAMPOVERDE DI APRILIA (ITALY)

- The Campoverde di Aprilia plant in Italy mainly supplies the active ingredients used in the preparation of the various pharmaceutical specialties produced by Recordati but it is also a well-established independent producer of a number of active and intermediate ingredients for the international pharmaceutical industry.
- It is one of the first European facilities to undergo inspections by the U.S. Food and Drug Administration (FDA).
- The U.S. has become, and continues to be, the primary outlet market for its production.
- The Campoverde site extends over approximately 375,000 sq. m., with an operational area of 35,000 sq. m., and produces approximately 600 MT/year of finished goods with approximately 4,000 MT/year of semi-finished goods handled internally.
- High-tech systems are employed to manage particularly delicate processes and investments are continuously made to enhance the technological and production capacity of the plant.
- The Research & Development laboratories are fitted with the latest equipment providing high containment and innovative synthetic technologies.
- The extremely versatile pilot plant is equipped for the small-scale production of active ingredients, in accordance with cGMP, and significant investments have been made to expand the range of technologies and operating conditions.
- The plant operates in compliance with current Good Manufacturing Practice



(cGMP) and is regularly inspected or surveilled by national and international authorities such as AIFA (Agenzia Italiana del Farmaco), the FDA (Food and Drug Administration), ANVISA (the Brazilian agency), PMDA (the Japanese Ministry of Health), and the KFDA (Korean Food and Drug Administration).

- The environmental management system is certified according to the UNI EN ISO 14001:2015 standards, and is inspected on an annual basis.
- In 2022, the technology transfer of osilodrostat, Isturisa's API, manufacturing process was completed. Validation batches were flawlessly manufactured and the regulatory file submitted to the Authorities.

The manufacturing licence was granted in 2023 by the Italian Ministry of Health.

- Various initiatives to recover and re-use chemical raw materials used in production processes are in place.
- At the site, Recordati has also started a three-year project aimed to the installation of a 10 MWp photovoltaic power generation facility and to the downsizing of the methane-based cogeneration unit currently operated. These measures will provide a significant reduction of the Recordati carbon footprint, also triggered by an increasingly efficient use of electric power.



CORK (IRELAND)

- To guarantee adequate and continuous supply of active ingredient lercanidipine HCl, in 2005, a new dedicated plant was built in Cork, Ireland. This facility has an automated process control system which ensures constant high-quality production.
- The plant is certified to cGMP (current Good Manufacturing Practice) standards and covers a surface area of around 43,000 sq. m., with an installed area of 8,300 sq. m.
- The continuous commitment to reduce and improve the use of energy was recognised in 2012 with the National Energy Efficiency Award, which is promoted by the Sustainable Energy Authority of Ireland

(SEAI), and in 2013 by the European Energy Efficiency Award, promoted by the Chemical European Federation Industry Council (CEFIC).

- In 2016, the site was extended, enlarging the two buildings housing the administration and quality control laboratories. Photovoltaic panels for the generation of electricity were installed in 2022 for a total area of 1,100 sq. m. providing 10% of the site electricity demand.
- Additionally, in 2024, a digital manufacturing project using Artificial Intelligence was initiated to enhance efficiencies and optimise chemical processes by leveraging the plant's high level of automation.

QUALITY AND SAFETY

A PERMANENT EFFORT IS MADE TO KEEP PRODUCTION LINES AND AREAS AT THE FOREFRONT OF TECHNOLOGY, WITH RELEVANT INVESTMENTS AIMED AT CONTINUOUSLY IMPROVING QHSE MANAGEMENT AND DEVELOPING PRODUCTION CAPACITY, EFFICIENCY AND FLEXIBILITY IN ORDER TO OFFER THE HIGHEST POSSIBLE LEVELS OF PATIENT HEALTH AND SAFETY.

All medicinal products are produced in accordance with the provisions of Good Manufacturing Practices (GMPs) in plants authorised by the relative local and non-European regulatory bodies. The Group's plants periodically undergo inspections and audits to ascertain compliance with current


legislation and applicable procedures. Furthermore, all third-party production facilities used by Recordati are subject to periodic audits, verifying the existence of the necessary regulatory authorisations required and ascertaining that all manufacturing and control activities are conducted in compliance with GMPs.

Manufacturing processes at Recordati's sites involve rigorous and complete preliminary controls of the batches of raw materials and packaging materials received. This occurs before their use in the established manufacturing and packaging processes.

In almost all cases, these controls are conducted at the Quality Control laboratories located within our plants. If external laboratories are used, these are selected and monitored according to the same rigorous procedure adopted by Recordati for third-party manufacturing facilities.

In both cases, the Quality Control laboratories must be expressly authorised and certified to perform these control activities, with inspections performed by national and international regulatory agencies. Each batch of medicines is subject to a preliminary quality

control procedure prior to its release onto the market, with the approval for distribution granted only in the event that the batches comply completely with the specifications authorised by the relevant Regulatory Authorities.



TECH TRANSFER AND LIFECYCLE MANAGEMENT

THANKS TO A SYSTEMATIC PROCESS OF TRANSFERRING KNOWLEDGE, SKILLS, TECHNOLOGIES AND OF MANAGING THE ENTIRE LIFE CYCLE OF A PRODUCT FROM ITS CONCEPTION, THROUGH DESIGN AND MANUFACTURE TO SERVICE, A RICH PORTFOLIO OF TECHNOLOGY TRANSFER PROJECTS ARE IN PLACE WITH GREAT AMBITIONS.

The projects range across RD and SPC business units, both on traditional technologies and biotechnologies. They focus on manufacturing and control processes by ensuring the supply quality and continuity, improving batch losses, yield and enabling increasing production.

Furthermore, small molecules and biotech are two main categories of on-going TT projects. The first category focuses primarily on process scale-up, analytical and manufacturing methods transfer as they may involve modifying reaction conditions or integrating continuous manufacturing technologies.

On the other hand, Technology Transfer in biotech, on top of the classical analytical and manufacturing methods transfer, focuses heavily on ensuring product consistency, as even slight variations can impact safety and efficacy, covering, for example, cell line and culture process transfer, upstream and downstream process transfer biosafety and contamination control.

COMMITMENT, RIGOUR, CAPABILITY

07. RESEARCH & DEVELOPMENT AT RECORDATI

WE CONTINUOUSLY DEVELOP NEW SPECIALTIES ORIGINATING EITHER INTERNALLY OR ACQUIRED THROUGH DEVELOPMENT AGREEMENTS WITH OTHER PHARMACEUTICAL COMPANIES AND RESEARCH INSTITUTES.

Commitment, scientific rigour, capability and highly-specialized personnel allow us to develop new treatments and build an innovative product pipeline.



INVESTMENT

286 Million Euros

in Research & Development in 2024
(includes depreciation relating to the purchase of new products)



INVESTMENT

+11.8%

in Research & Development
compared to 2023



OUR PRODUCT DEVELOPMENT PIPELINE

NAME	INDICATION	DEVELOPMENT STATUS
REC 0545	Acute decompensation episodes in Maple Syrup Urine Disease (MSUD) or leucinosi	Regulatory process ongoing in EU
ISTURISA®	Endogenous Cushing’s Syndrome/ Cushing’s Disease	Approved in the U.S., Europe, Switzerland, Australia, Israel and Japan. Filed in other countries. U.S. regulatory decision for Cushing’s Syndrome sNDA in mid-2025.
PASIREOTIDE	Post-Bariatric Hypoglycaemia	Phase II enrolment expected to be completed in mid-2025
CYSTADROPS®	Corneal cystine crystal deposits in patients with cystinosis	Approved in the U.S. and Europe. New, more convenient dropper approved in U.S. at the end of 2024.
CARBAGLU®	Hyperammonemia due to NAGS deficiency and to the main organic acidemias	Approved in China
QARZIBA®	Treatment of high-risk neuroblastoma patients who achieved at least a partial response at the chemotherapeutical induction, followed by myeloablative therapy and stem cell transplantation, and of patients with relapsed or refractory neuroblastoma	Approved in the EU, UK, Australia, Brazil, China Hong Kong, Israel, Russia and Taiwan. In the U.S., Recordati is planning further interactions mid-2025 with the FDA.
SYLVANT®	Treatment of idiopathic Multicentric Castleman Disease (iMCD)	Approved in over 40 countries including EU, U.S. and China. Potential indication expansion evaluation ongoing.

HONOURING EXCELLENCE IN RESEARCH: THE ARRIGO RECORDATI PRIZE

Established in 2000 in memory of Arrigo Recordati, the Prize is an international award that aims to promote scientific research and to inspire biomedical discoveries benefiting people worldwide:

- A € 100,000 research grant is awarded to an individual or a project in recognition of excellence in research into orphan diseases treatment.
- The winner is chosen by an independent panel of internationally recognised experts, who have provided leadership in the field of rare diseases throughout their long careers.

The 2024 edition was dedicated to the promotion and recognition of excellence in research on paediatric oncology, specifically neuroblastoma.

At the 5th Annual Meeting of the European Society for Paediatric Oncology (SIOPE) held in Milan, the 11th edition of the International Prize for Scientific Research Arrigo Recordati was awarded to Dr. Adam Durbin, M.D., PhD., from St. Jude Children’s Research Hospital in Memphis, US. The Prize recognises his work in providing new potential therapeutic strategies for children with neuroblastoma.



LAUNCH OF THE CALL FOR APPLICATIONS FOR THE 12TH EDITION OF THE ARRIGO RECORDATI PRIZE AT SIOPE CONGRESS 2025 IN AMSTERDAM.

The 2026 Award will be dedicated to the promotion and recognition of excellence in research within paediatric oncology, specifically sarcomas, reflecting Recordati’s strong commitment to rare diseases through its division Recordati Rare Diseases.

AN IDEAL PARTNER

08. PARTNERING WITH RECORDATI

THANKS TO OUR ABILITY TO DEVELOP SUCCESSFUL RELATIONSHIPS, WE HAVE IMPLEMENTED A STRATEGY OF PARTNERING WITH COMPANIES WITH HIGH STANDARDS IN THE PHARMACEUTICAL SEGMENT.

We are a partner of choice due to our unique structure, bringing treatment options across Specialty & Primary Care, Consumer Healthcare, and Rare Diseases.

We have fully-integrated operations across Research & Development, chemical and finished product manufacturing through to commercialisation.

STRONG CAPABILITIES & GLOBAL REACH

- Fully-integrated company with successful track record in developing, registering, manufacturing and commercialising medicinal products.
- Global footprint with direct presence in around more than 150 countries and partnerships in remaining markets.

We have a strong track record in generating value through partnerships with other pharmaceutical companies, whether they are local or global players.

We are committed to generating further growth through mutually-beneficial R&D collaborations, licence agreements and acquisitions.

FOCUS

- A “local brilliance” commercial approach to each and every market, ensuring growth opportunities are maximised.
- Growth driven by focus on few strategic products that add value to patients, payers and physicians.
- We treat each partnered product as if it were our own.

BUSINESS DEVELOPMENT TRACK RECORD

- Creative and flexible deal structures to share value with partners.
- Long-lasting strategic partnerships.
- More than 35 transactions completed in the last 15 years.

OUR BUSINESS DEVELOPMENT STRATEGY

WE ARE LOOKING FOR IN-LICENSING AND ACQUISITION OPPORTUNITIES AND TECHNOLOGIES TO STRENGTHEN OUR PIPELINE AND PORTFOLIO AND FOSTER INNOVATION IN THE FOLLOWING AREAS:



RARE DISEASES

Innovative products from Clinical Proof of Concept programmes to marketed products, in all therapeutic areas and with a particular focus on:

- Rare endocrinology.
- Rare metabolism.
- Rare oncology.
- Rare hematology.

SPECIALTY & PRIMARY CARE

Innovative products from Phase 2b clinical stage to marketed products in:

- Cardio-metabolism.
- Urology/ uro-oncology.
- Gastrointestinal.

Established and marketed products across any therapeutic area.















CONSUMER HEALTHCARE

Well established and marketed CHC products mainly in categories such as:

- Digestive health.
- Women’s health & intimate care.
- Respiratory health.



SELECTED PARTNERSHIPS

LICENSOR	TRADEMARK	THERAPEUTIC AREA
	Juxtapid®	Rare metabolism
	Qarziba®	Rare oncology
	Fotivda®	Rare oncology
	Reagila®	CNS
	Avodart® and Combodart®/ Duodart®	Urology
	Ledaga®	Onco-dermatology
	Urorec®/Silodyx™/Silosin®	Urology
	Livazo®/Alipza®	Cardiometabolism
	Reselip®	Cardiometabolism
	Fortacin™	Urology
	Rizmoic®	Gastrointestinal
	Vitaros®/Virirec®	Urology
	Peptazol®	Gastrointestinal
	Eligard®	Uro-oncology

* Trademarks are owned by or licensed to the GSK group of companies



SUSTAINABLE AND RESPONSIBLE GROWTH



Formalised D&I strategy and policy.
A global network of more than **60 D&I Champions** was launched.



Formalised **Environment, Health and Safety Policy**, and **Human Rights Policy**.



In 2024, **installation of solar panels** was **completed in Türkiye**, reaching **installed power of approximately 860 kWp**, in addition to systems already installed in 2022 in Ireland and Spain. By 2026, the Group aims to install further new systems at plants in Italy (Campoverde) and Tunisia, as well as expanding the system in Spain, reaching installed power of 11,000 kWp.



Continued to purchase **100% renewable energy**, in countries where this is possible*.



Defined a **roadmap** to obtain **ISO certifications** for various Group plants.




Reduce Scopes 1 and 2 CO₂eq emissions by 20% by 2030, using 2022 as a baseline.



Around **1,600 patients** affected by rare diseases supported through the **Patient Assistance Program**, the **Co-Pay Assistance Program** and similar programmes.



59 ESG Audits: 44 new suppliers audited in 2024 (via desk audits) on ESG topics, and 15 follow-ups performed by an independent third party.



Around 180 supplier audits conducted by the pharmaceutical and chemical-pharmaceutical division, mainly on product quality and safety.



Approximately **€ 2.7 million in donations** to the community**.

* This figure excludes Tunisia, where renewable energy is not available. Please refer to the 2024 Sustainability Statement for further details.
** In the form of both monetary and product donations (measured at market value).

09. RECORDATI'S COMMITMENT TO SUSTAINABILITY

THE VALUES THAT HAVE ALWAYS INSPIRED AND GUIDED US.

We have a long history of entrepreneurial passion, a strong reputation and a desire to continue growing and creating value in an ethical, enduring, and sustainable way, all while respecting the laws and regulations that apply in the countries in which we operate, protecting people and the environment, and supplying safe, high-quality products.



Our efforts to sustainability are recognised by the main ESG indices and ratings.

Confirmed in the **FTSE4Good** Index Series

Confirmed **A** rating from MSCI ESG Research*

EcoVadis awarded the Recordati group with a **"Gold"** medal

Rated **C+ "Prime"** status by ISS ESG

Inclusion in **MIB ESG** index launched by Euronext and Borsa Italiana

* The use by the Recordati group of any MSCI ESG Research LLC or its affiliates ("MSCI") data, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement, recommendation, or promotion of Recordati Group by MSCI. MSCI services and data are the property of MSCI or its information providers, and are provided 'as-is' and without warranty. MSCI names and logos are trademarks or service marks of MSCI.

OUR SUSTAINABILITY PLAN

Our Sustainability Plan is the tool used to share our future trajectory with our stakeholders: it represents an expression of the ambitions of our group and the commitments we wish to prioritise in order to promote sustainable and responsible growth.

THE 5 ESG STRATEGIC PILLARS

PATIENT CARE

Our ambition

We are open to partnering and dedicated to discovering and developing innovative, value-added products that improve quality of life and help people to enjoy longer, healthier and more productive lives. We wish to offer our patients fast, widespread and sustainable access to our products.

PEOPLE CARE

Our ambition

We are committed to creating a safe and inclusive working environment where everyone can express their talents. Our Employees are our most important asset and, therefore, we recognise and value the role that each person plays in the success of our business.

We aim to create shared value and positively contribute to sustainable development where we operate, aware of the importance of dialogue, collaboration and respect for the community.

ENVIRONMENTAL PROTECTION

Our ambition

Improving human health is the cornerstone of our purpose, but we are aware that the health and well-being of present and future generations and the health of our planet are closely interlinked. With this in mind, we want to take conscious action by working to preserve natural resources and biodiversity and contribute to the fight against climate change by minimising our environmental impact.

RESPONSIBLE SOURCING

Our ambition

We want to build relationships based on transparency and trust, sharing our values with suppliers and strategic partners. We are committed to constantly promoting respect for ethical, environmental and social aspects along the entire value chain.

ETHICS AND INTEGRITY

Integrity is our founding value, and we lead by example. The principles of honesty and transparency towards our Shareholders and Stakeholders guide our daily actions.

3 GOOD HEALTH AND WELL-BEING

4 QUALITY EDUCATION

5 GENDER EQUALITY

6 CLEAN WATER AND SANITATION

7 AFFORDABLE AND CLEAN ENERGY

8 DECENT WORK AND ECONOMIC GROWTH


9 INDUSTRY, INNOVATION AND INFRASTRUCTURE

12 RESPONSIBLE CONSUMPTION AND PRODUCTION

13 CLIMATE ACTION

16 PEACE, JUSTICE AND STRONG INSTITUTIONS

RECORDATI'S COMMITMENT TO SUSTAINABILITY



SUPPORT FOR LOCAL COMMUNITIES

We believe that contributing to the well-being of the community and dedicating part of our resources to acts of solidarity are not merely the fulfilment of company obligations or professional duty, but rather a moral imperative.



€ 2.7 million

in donations to the community (including monetary and product donations measured at market value)



24,000 approximately planted trees

From 2021 to 2024 (approx. 5 per employee). Having successfully completed the Forestami project in Italy and other planting initiatives in Tunisia for the three years 2021–2023, in 2024, the Turkish branch sponsored the planting of approx. 10,000 trees in the reforestation area of Kilis Yeniyurt, which was hit by the 2023 earthquake, with support from the Tema Foundation.



MULTIPLE COMPANY VOLUNTEERING PROJECTS

In 2024 many initiatives supported the local communities in which we operate through the direct participation of our people. One of the most prominent areas was the participation of people in voluntary work to protect the natural environment.



HUMANITARIAN EMERGENCY: SUPPORTING FLOOD RELIEF EFFORTS

In response to the devastating floods in Spain, our local team decided to support the relief efforts through a donation to Casa Caridad, a non-profit organization active in providing aid in the affected areas. Casa Caridad assisted many people in need from the very first hours after the extreme rainfall and flash flooding.



GROUP COMPANIES AND OFFICES

ITALY

RECORDATI S.P.A.
INNOVA PHARMA S.P.A.
ITALCHIMICI S.P.A.
NATURAL POINT S.R.L.
RECORDATI RARE DISEASES
ITALY S.R.L.

Headquarter and Registered Office:
Via M. Civitali, 1
20148 Milan (Italy)
Ph. +39 02 48787.1
www.recordati.com

Operational Office:
Via Roncaglia, 12
20146 Milan (Italy)

Specialty & Primary Care:
Ph. +39 02 48787.1

Rare Diseases:
Ph. +39 02 48787.173

Pharmaceutical
Manufacturing Plant:
Via M. Civitali, 1
20148 Milan (Italy)
Ph. +39 02 48787.1

Pharmaceutical Chemical Plant:
Via Mediana Cisterna, 4
04011 Campoverde di Aprilia, LT
(Italy)
Ph. +39 06 92900010

ARGENTINA

RECORDATI ARGENTINA S.R.L.
Registered Office:
Suipacha 1111 - 11º piso / floor
(C1008AAW) Buenos Aires
Argentina

AUSTRALIA

RECORDATI RARE DISEASES
AUSTRALIA PTY LTD.
Registered Office:
Suite 1802, Level 18,
233 Castlereagh Street
NSW 2000 Sydney (Australia)
Ph. +61 (0) 408 061403
Email:
RRDAustraliainfo@recordati.com

AUSTRIA

RECORDATI AUSTRIA GMBH
Registered Office:
c/o Next Pharma Logistiscs Julius
Raab-Straße 26,
A-2203 Großbeersdorf (Austria)
Ph: +43 2279 51018-0

BENELUX

RECORDATI BV / S.R.L
Registered Office:
Avenue du Bourgmestre Demunter,
5 Boite 4
1090 Jette (Belgium)
Ph.: +32 2 461.01.36
Email: infobenelux@recordati.com

RECORDATI NETHERLANDS B.V.
Registered Office:
Beechavenue, 54
1119PW Schiphol-Rijk (Netherlands)

BRAZIL

RECORDATI RARE DISEASES
COMÉRCIO DE MEDICAMENTOS
LTD A
Registered Office:
Barueri, Estado de São Paulo,
na Avenida Piraíba, 355, 2º andar,
sala 06
Centro Comercial Jubran,
CEP 06460-121 (Brazil)

Branch Registered Office:
Cidade de São Paulo, estado
de São Paulo na Rua Surubim,
nº 504, conjunto 31
Edifício Berrini Park, Cidade
Monções, CEP 04571-050 (Brazil)

BULGARIA

RECORDATI BULGARIA LTD.
Registered Office:
84 "Al. Stamboliiski" Blvd.
Floor 8, Office No. 44
1303 Sofia (Bulgaria)
Ph. +359 2 829 39 37
Email: Penkova.d@recordati.com

Trade Representation Office:
84, "Al. Stamboliyski" Blvd.
Floor 8, Office No. 44
1303 Sofia (Bulgaria)

CANADA

RECORDATI RARE DISEASES
CANADA INC.
Registered Office:
333 Bay Street, Suite 2400
M5H 2T6 Toronto, ON (Canada)
Email: infocanada@recordati.com

Operational Office:
3080 Yonge Street, Suite 6060
M4N 3N1 Toronto, ON (Canada)

CHINA
RECORDATI (BEIJING)
PHARMACEUTICAL CO., LTD.
Registered Office:
Unit 03, 05, 1T01, Office 26, 26th
Floor, No. 81, Jianguo Road
Chaoyang District, Beijing (China)

COLOMBIA

RECORDATI RARE DISEASES
COLOMBIA S.A.S
Registered Office:
Carrera 7 N° 127, 48 Oficina 901,
Edificio 128, Centro Empresarial
Bogotá D.C. (Colombia)
Ph. +57 1 6472780
Email:
RRDColombiainfo@recordati.com

CZECH REPUBLIC AND SLOVAKIA

HERBACOS RECORDATI S.R.O.
Registered Office:
Generála Svobody 335
Rosice, 533 51 Pardubice
(Czech Republic)
Ph. +420 227 200 722
Email: recordati@recordati.cz

RECORDATI SK S.R.O
Registered Office:
Vavrinecká 5
831 52 Bratislava (Slovakia)

Pharmaceutical
Manufacturing Plant:
Štrossova 239
530 03 Pardubice (Czech Republic)
Ph. +420 466 614 055
Email: recordati@recordati.cz

FRANCE

RECORDATI RARE DISEASES
S.A.R.L
BOUCHARA-RECORDATI S.A.S
FIC MÉDICAL SARL (WITH
REPRESENTATIVE OFFICES IN
SEVERAL C.I.S. COUNTRIES)
LABORATOIRES BOUCHARA
RECORDATI S.A.S
Registered Office:
Tour Hekla
52, avenue du Général De Gaulle
92800 Puteaux (France)
Ph. +33 1 45191000
Email:
RRDFranceinfo@recordati.com

Pharmaceutical
Manufacturing Plant:
Parc Mécatronic
03410 Saint Victor (France)
Ph. +33 4 70037900

Packaging and Distribution Center
(dedicated to products for Rare
Diseases):
Eco River Parc, 30 Rue des Peupliers
92752 Nanterre (France)
Ph. +33 1 70 82 44 31

GERMANY

RECORDATI PHARMA GMBH
Registered Office:
Eberhard-Finckh-Str. 55
89075 Ulm (Germany)
Ph. +49 731 7047.0

RECORDATI RARE DISEASES GERMANY GMBH

Registered Office:
Eberhard-Finckh-Str. 55
89075 Ulm (Germany)
Ph. +49 731 140 554 0
Email:
RRDGermanyinfo@recordati.com

Recordati Rare Diseases Germany
GmbH Branch Office Munich
Elsenheimerstrasse 41
80687 Munich (Germany)

GREECE

RECORDATI HELLAS
PHARMACEUTICALS S.A.
Registered Office:
7, Zoodochou Pigis Str.
15231 K. Chalandri
Atene (Greece)
Ph. +30 210 6773822

IRELAND

RECORDATI IRELAND LTD.
Registered Office:
Raheens East
Ringaskiddy, Co. Cork
P43 KD30 (Ireland)
Ph. +353 21 437 94 00

Recordati Ireland Limited Sede
Secondaria Italiana
Branch registered office:
Via M. Civitali, 1
20148 Milan (Italy)

JAPAN

RECORDATI RARE DISEASES
JAPAN K.K.
Registered Office:
4-8-18, Akasaka
Minato-ku, Tokyo (Japan)
Ph. +81 3 4510 2910
Email: RRDJapaninfo@recordati.com

KOREA

RECORDATI KOREA, CO., LTD.
Registered Office:
DongHee Building, 4th Fl. 302
Gangnamdae-ro, Gangnam-gu
06236 Seoul (Korea)

MIDDLE EAST

RECORDATI RARE DISEASES
MIDDLE EAST FZ-LLC
Registered Office:
Dubai Healthcare City
Building 25, Unit 205-206,
P.O. Box 505075
Dubai (UAE)
Ph. +971 4 363 5454
Email:
RRDMiddleeastinfo@recordati.com



RECORDATI RARE DISEASES FZCO

Registered Office:
Building 8E, Office 402, DAFZA, P.O.
Box: 505075
Dubai (UAE)

RECORDATI RARE DISEASES MENA RHQ

Registered Office:
Riyadh (Saudi Arabia)

MEXICO

RECORDATI RARE DISEASES S.A.
DE C.V.
Registered Office:
Avenida Ejercito Nacional 418-307
Col. Polanco V Sección
11560 Miguel Hidalgo,
Ciudad de México (Mexico)
Email:
RRDMexicoinfo@recordati.com

Operational Office:
IZA Torre Prisma
Av. Insurgentes Sur 1647 Floor 4
Office 421
Col. San José Insurgentes
03900 Delegación Benito Juárez,
Ciudad de México (Mexico)
Ph. +525526140975

POLAND

RECORDATI POLSKA SP. Z O.O.
Registered Office:
al. Armii Ludowej 26
00-609 Warsaw (Polaska)
Ph. +48 22 206 84 50

PORTUGAL

JABA RECORDATI S.A.
CASEN RECORDATI PORTUGAL
UNIPESOA L.D.A.
BONAFARMA - PRODUTOS
FARMACÉUTICOS S.A.
JABAFARMA - PRODUTOS
FARMACÉUTICOS S.A.
Registered Office:
Av. Jacques Delors
Ed. Inovação 1.2, Piso 0 - Taguspark
2740-122 Porto Salvo (Portugal)
Ph. +351 21 4329.500

RECORDATI UK LTD - SUCURSAL EM PORTUGAL

Registered Office:
Av. Jacques Delors
Ed. Inovação 1.2, Piso 0 - Taguspark
2740-122 Porto Salvo (Portugal)
Ph.+351 (0) 308801554

ROMANIA

RECORDATI ROMANIA S.R.L.
Registered Office:
92-96 Izvor street,
Office B, 4th floor, Rooms 2-8,
5th District
Bucarest (Romania)
Ph. +40 21 667 17 41 - 2

RUSSIA AND C.I.S.

RUSFIC LLC
OOO ACCENT LTD.
Registered Office:
Krasnopresnenskaya
Naberezhnaya 12
Entrance 7, floor 6, premises 2
123610, Moscow
(Russian Federation)
Email: info@rusfic.com
Email: RRDRussiainfo@recordati.com

SPAIN

CASEN RECORDATI S.L.
Registered Office:
Autovia de Logroño, km. 13,300
50180 Utebo, Zaragoza (Spain)

Operational Office:
Via de las Dos Castillas, 33 - 3º planta
Ática, Edificio 7
28224 Pozuelo de Alarcón,
Madrid (Spain)
Ph. + 34 91 351 88 00
Ph. + 34 91 659 15 50

Pharmaceutical
Manufacturing Plant:
Autovia de Logroño, km. 13,300
50180 Utebo, Zaragoza (Spain)
Ph. + 34 97 646 26 26

RECORDATI RARE DISEASES SPAIN, S.L.

Registered Office:
Autovia de Logroño, km. 13,300
50180 Utebo, Zaragoza (Spain)
Ph. + 34 97 646 26 26

Operational Office:
Via de las Dos Castillas, 33 - 3º planta
Ática, Edificio 7
28224 Pozuelo de Alcaròn,
Madrid (Spain)
Ph. + 34 91 351 88 00
Ph. + 34 91 659 15 50

SWEDEN

RECORDATI AB.
Registered Office:
Berzeliusväg 8,
171 65 Solna, Sweden
Ph. +46 8 545 80 230
Email: InfoNordic@recordati.com

SWITZERLAND

RECORDATI AG
Registered Office:
Lindenstrasse, 8
6340 Baar (Switzerland)
Ph. +41 41 769.1000
Email: info@recordati.ch

RECORDATI AG, RARE DISEASES BRANCH

Registered Office:
Uferstrasse, 90
4057 Basel (Switzerland)
Ph. +41 58 658 10 00
Email:
info.rarediseases.ch@recordati.com

Pharmaceutical
Manufacturing Plant:
Lichtstrasse, 35
4056 Basel - (Switzerland)
Ph. +41 58 658 10 00

EUSA PHARMA (CH) GMBH

Registered Office:
C/O Curator & Horwath AG
Zweigniederlassung Zug
Industriestrasse 7
6300 Zug (Switzerland)
Ph. +41 (0) 800001415

TUNISIA

OPALIA RECORDATI S.A.R.L.
Registered Office:
27 Avenue De La Livre Sterling
Les Berges du Lac 2
1053 Tunis (Tunisia)
Ph. +216 70 559 070-064
Email:
communication@opalia.com.tn

OPALIA PHARMA S.A.
Registered Office
and Pharmaceutical
Manufacturing Plant:
Zone Industrielle de Kalaat
El Andalous,
Lot 3 à 8 - 2022 Ariana (Tunisia)

TÜRKİYE

RECORDATI İLAÇ SANAYİ VE
TİCARET A.S.
Registered Office
and Manufacturing Plant:
Çerkezköy Organize Sanayi Bölgesi
Karaağaç Mahallesi Atatürk
Caddesi No:36 Kapaklı
59510 Tekirdağ İstanbul (Türkiye)

Administrative Office:
Maslak Mah. Sümer Sok. No: 4
Maslak Office Building
İstanbul (Türkiye)
Ph. +90 212 401 91 00

Pharmaceutical
Manufacturing Plant:
Çerkezköy Organize Sanayi Bölgesi
Karaağaç Mahallesi Atatürk
Caddesi No:36 Kapaklı
59510 Tekirdağ İstanbul (Türkiye)
Ph. +90 282 999 16 00

RECOFARMA İLAÇ VE
HAMMADELERİ SANAYİ VE
TİCARET LİMİTED ŞİRKETİ
Maslak Mahallesi Sümer Sk. Kar Plaza
Apt. No: 4/21
Sarıyer/İstanbul (Türkiye)

UKRAINE

RECORDATI UKRAINE LLC
Registered Office:
40, Hlybochyska Str.
04050 Kyiv (Ukraine)
Ph. +380 44 351 18 63

UNITED KINGDOM

RECORDATI PHARMACEUTICALS
LTD.
Registered Office:
Breakspear Park
Hemel Hempstead HP2 4TZ
(United Kingdom)
Ph. +44 1 49 1576 336
Email:
customerservice@recordati.com

RECORDATI UK LTD

Registered Office:
Breakspear Park
Hemel Hempstead HP2 4TZ
(United Kingdom)
Ph.+44 (0) 330 500 1140

RECORDATI RARE DISEASES UK LTD.

Registered Office:
Greengarth, Thicket Grove,
Maidenhead
Berkshire, SL6 4LW (United Kingdom)
Email: infoRRDUK@recordati.com

Operational Office:
Breakspear Park
Hemel Hempstead HP2 4TZ
(United Kingdom)
Ph. +44 1 49 1576 336
Email:
customerservice@recordati.co.uk

UNITED STATES

RECORDATI RARE DISEASES
INC.
Registered Office:
c/o the Prentice – Hall Corporation
System, Inc., 2711 Centerville Road,
Suite 400,
Wilmington, County of New Castle
19801 Delaware (USA)
Email:
info@recordatirarediseases.com

Operational Office:
440 Rte 22 E, Suite 205
Bridgewater
08807 New Jersey (USA)



The information on the pharmaceutical specialties and other products of the Recordati group contained in this document is intended solely as information on the Recordati group's activities and therefore, as such, it is not intended as medical scientific indication or recommendation, nor as advertising. iStock images are included for illustrative purposes only.



RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

HEADQUARTER

Via Matteo Civitali, 1
20148 Milan, Italy
Ph. +39 02 48 787.1
www.recordati.com

